Clinical trials: End-stage Heart Failure
End-stage Heart Failure
LVAD Versus GDMT in Ambulatory Advanced Heart Failure Patients
Heart failure is a severe disease affecting approximately 1-2% of the adult population in developed countries and around 26 million people worldwide.
- Trial name
- AMBU-VAD (NCT04768322)
- Testing
- HeartMate 3 TM Left Ventricular Assist System, Guideline Directed Medical Therapy
- Where
- 8 sites in France
- Volunteers
- 92 people
- Sponsor
- Hospices Civils de Lyon
End Stage Liver DIsease
Comparison of Hypothermic Versus Normothermic Ex-vivo Preservation.
Study groups: The study is a multicenter (Pisa and Milan), prospective, randomized study comparing D-HOPE (HMP) vs NMP in DCD and ECD-DBD (extended criteria brain-dead donors).
- Trial name
- DCDNet (NCT04744389)
- Testing
- Hypothermic Machine Perfusion, Normothermic Machine Perfusion
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Azienda Ospedaliero, Universitaria Pisana
Renal Replacement Therapy, Renal Dialysis
A Clinical Trial of IntensiVE Dialysis
This study will assess clinical outcomes of extended weekly hours of haemodialysis (>= 24 hours per week) compared with standard hours of haemodialysis (<=18 hours/week) in people with ESKD.
- Conditions
- Renal Replacement Therapy, Renal Dialysis, End Stage Kidney Disease, End Stage Renal Disease
- Trial name
- ACTIVE (NCT00649298)
- Testing
- haemodialysis
- Where
- 40 sites in Australia, Canada and 2 more
- Volunteers
- 200 people
- Sponsor
- The George Institute
Cardiovascular Diseases, Heart Diseases
Genetic Analysis of Human Hypertensive End Stage Renal Disease (H-ESRD)
To identify genes causing hypertensive end-stage renal disease (H-ESRD) in high risk African-American populations
- Conditions
- Cardiovascular Diseases, Heart Diseases, Hypertension, Kidney Failure, Chronic
- Trial name
- NCT00005536
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
End Stage Renal Failure
Effect of Reducing Phosphorus Absorption on Cardiac Biomarkers in Hemodialysis Patients
Hyperphosphatemia and elevated cardiac biomarkers are two key characteristics of patients in end stage renal diseases(ESRD),however the majority of whom are in the absence of acute coronary syndrome(ACS).
- Trial name
- NCT01781156
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai 10th People's Hospital
Endocrine System Diseases, Thyroid Diseases
Endocrine Changes and Their Correction in Heart and Lung Transplant Recipients and Donors
The aim of this study is to assess the impact of endocrine changes and their correction on survival and organ function in heart and lung transplant recipients.
- Conditions
- Endocrine System Diseases, Thyroid Diseases, Cortisol Deficiency, Diabetes Insipidus
- Trial name
- NCT04351945
- Testing
- Blood test
- Where
- Hungary
- Volunteers
- 100 people
- Sponsor
- Semmelweis University Heart and Vascular Center
End Stage Chronic Renal Failure, Congestive Heart Failure (CHF)
The FILTRATE Trial: High-Rate Ultrafiltration for Intravascular Congestion
The purpose of this study is to evaluate whether a personalized, high-rate fluid removal strategy guided by ultrasound is as safe and effective as the standard fluid removal rate for patients with advanced kidney disease who are…
- Conditions
- End Stage Chronic Renal Failure, Congestive Heart Failure (CHF), Intravascular Congestion, Fluid Overload
- Trial name
- FILTRATE (NCT07705269)
- Testing
- High-rate ultrafiltration, Standard fluid removal
- Where
- Mexico
- Volunteers
- 70 people
- Sponsor
- Universidad Autonoma de Nuevo Leon
Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Family Palliative and End-of-Life Care for Advanced Heart Failure
Overall objective is to test whether the 5-weekly family home palliative and end-of-life care (FamPALcare) intervention educational and supportive sessions will improve rural home end-of-life and palliative care (EOLPC) for…
- Trial name
- NCT04153890
- Testing
- FamPALcare
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- West Virginia University
Heart Failure with Reduced Ejection Fraction, End Stage Renal Disease on Dialysis
Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal Disease
In patients with ESRD, up to 20% of patients suffer from HFrEF, leading to significant CV morbidity and mortality. Several drug classes that provide survival benefits for patients with HFrEF, including SGLT2i, lack data regarding…
- Trial name
- EMPA-RRED (NCT06249932)
- Testing
- Empagliflozin 25 MG
- Where
- 2 sites in Taiwan
- Volunteers
- 95 people
- Sponsor
- National Taiwan University Hospital
Congestive Heart Failure, Low Cardiac Output
Losartan in Decompensated Heart Failure
The dual blockade of the renin-angiotensin-aldosterone system with an angiotensin-converting enzyme inhibitor and an angiotensin-receptor blocker used together in heart failure patients has been demonstrated to be beneficial.
- Trial name
- NCT01857999
- Testing
- Losartan
- Where
- Brazil
- Volunteers
- 21 people
- Sponsor
- InCor Heart Institute
Heart Failure
Stem Cell Therapy in Patients With Severe Heart Failure & Undergoing Left Ventricular Assist Device Placement
The purpose of this study is to determine if the delivery of cells just after implantation of left ventricular assist device will help to improve the pumping function of your heart and minimize heart enlargement in the future.
- Trial name
- ASSURANCE (NCT00869024)
- Testing
- Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Minnesota
Atrial Fibrillation, End Stage Renal Disease
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
This is a prospective, randomized, open-label, blinded end-point evaluation trial. The patient population consists of patients on hemodialysis who have atrial fibrillation (AF) and end-stage renal disease (ESRD) .
- Trial name
- RENAL-AF (NCT02942407)
- Testing
- apixaban, warfarin
- Where
- 58 sites in United States
- Volunteers
- 154 people
- Sponsor
- Christopher Granger, MD
Heart Failure, Hyperuricemia
Long-term Prednisone Use for End-stage Heart Failure
Patients with advanced (ACCF/AHA stage D) heart failure and hyperuricemia have high one-year mortality. Currently, there was no evidence-based therapy such as mechanically assisted circulatory support available in China.
- Trial name
- NCT02282683
- Testing
- prednisone
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Hebei Medical University
End Stage Heart Failure
Sildenafil for the Prevention of Right Heart Failure Following LVAD Implantation
Continuous-flow left ventricular assist devices (LVAD) move blood from the left ventricle (the largest chamber of the heart) to the aorta (the body's main artery) to help the heart better meet the needs of the body and to improve…
- Trial name
- NCT03356353
- Testing
- Sildenafil Citrate
- Where
- 4 sites in Canada
- Volunteers
- 24 people
- Sponsor
- University of Calgary
End-stage Heart Failure
Corheart 6 Left Ventricular Assist System Prospective, Multicenter, Single-arm Clinical Evaluation Trial
This study is to evaluate the safety and effectiveness of the Corheart 6 Left Ventricular Assist System (Corheart 6 LVAS) used for the treatment of end-stage heart failure.
- Trial name
- NCT05353816
- Testing
- Corheart 6 Left Ventricular Assist System
- Where
- 11 sites in China
- Volunteers
- 50 people
- Sponsor
- Shenzhen Core Medical Technology CO.,LTD.
End-stage Heart Failure, Left Ventricular Assist Device
LVAD Index and Clinical Outcomes in Continuous-Flow LVAD Patients
This single-center, observational study evaluated the LVAD index, defined as device-estimated pump flow divided by body surface area, in adult patients supported with continuous-flow left ventricular assist devices.
- Conditions
- End-stage Heart Failure, Left Ventricular Assist Device, Mechanical Circulatory Support
- Trial name
- LVAD-INDEX (NCT07633535)
- Testing
- HeartWare Ventricular Assist Device, HeartMate 3 Left Ventricular Assist Device
- Where
- Turkey (Türkiye)
- Volunteers
- 34 people
- Sponsor
- Gaziantep City Hospital
End-stage Heart Failure, Cardiomyopathies
VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Pivotal Trial
The purpose of this study is to evaluate the safety and effectiveness of VentrAssistTM LVAD in individuals who are awaiting heart transplants.
- Trial name
- NCT00483197
- Testing
- VentrAssistTM Left Ventricular Assist Device
- Where
- 29 sites in United States
- Volunteers
- 140 people
- Sponsor
- Ventracor
Hypertension, Coronary Disease
Analyzing How Genetics May Affect Response to High Blood Pressure Medications
High blood pressure is one of the most common health problems in the United States. There are many medications to treat high blood pressure, but there is a large variance in how people respond to these medications.
- Conditions
- Hypertension, Coronary Disease, Cerebrovascular Accident
- Trial name
- NCT00563901
- Where
- 2 sites in United States
- Volunteers
- 37,939 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Myocardial Fibrosis, End Stage Renal Failure on Dialysis
MRI Assessment of Myocardial Fibrosis Associated With Monocyte Phenotype in End Stage Renal Failure
Firstly, this study aims to understand how cardiac fibrosis mediated by inflammatory microvascular disease evolves during advanced chronic kidney disease and end stage renal failure and importantly how this changes with…
- Conditions
- Myocardial Fibrosis, End Stage Renal Failure on Dialysis, Chronic Kidney Disease, Stage IV (Severe), Chronic Kidney Disease Stage V
- Trial name
- CM3 (NCT03857633)
- Testing
- Cardiac MRI 1 - With Gadolinium Contrast, Cardiac MRI 2 - With Gadolinium Contrast, Cardiac MRI 3 - Without Gadolinium Contrast
- Where
- United Kingdom
- Sponsor
- Imperial College London
End Stage Renal Disease, Left Ventricular Hypertrophy
Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study
Kidney patients on dialysis commonly die because of heart disease. One of the biggest problems in their hearts is that the muscle wall of the heart thickens. This makes it less efficient.
- Trial name
- Altered (NCT01951404)
- Testing
- Allopurinol
- Where
- 3 sites in United Kingdom
- Volunteers
- 80 people
- Sponsor
- University of Dundee